Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency
Year: 2020
Type: article
Study design: Case Report
Abstract: Hypomorphic IL2RG mutations may lead to milder phenotypes than X-SCID, named variably as atypical X-SCID or X-CID. We report an 11-year-old boy with a novel c. 172C>T;p.(Pro58Ser) mutation in IL2RG, presenting with atypical X-SCID phenotype. We also review the growing number of hypomorphic IL2RG mutations causing atypical X-SCID. We studied the patient's clinical phenotype, B, T, NK, and dendritic cell phenotypes, IL2RG and CD25 cell surface expression, and IL-2 target gene expression, STAT tyrosine phosphorylation, PBMC proliferation, and blast formation in response to IL-2 stimulation, as well as protein-protein interactions of the mutated IL2RG by BioID proximity labeling. The patient suffered from recurrent upper and lower respiratory tract infections, bronchiectasis, and reactive arthritis. His total lymphocyte counts have remained normal despite skewed T and B cells subpopulations, with very low numbers of plasmacytoid dendritic cells. Surface expression of IL2RG was reduced on his lymphocytes. This led to impaired STAT tyrosine phosphorylation in response to IL-2 and IL-21, reduced expression of IL-2 target genes in patient CD4+ T cells, and reduced cell proliferation in response to IL-2 stimulation. BioID proximity labeling showed aberrant interactions between mutated IL2RG and ER/Golgi proteins causing mislocalization of the mutated IL2RG to the ER/Golgi interface. In conclusion, IL2RG p.(Pro58Ser) causes X-CID. Failure of IL2RG plasma membrane targeting may lead to atypical X-SCID. We further identified another carrier of this mutation from newborn SCID screening, lost to closer scrutiny.
Source: Journal of Clinical Immunology
Institutions: University of Helsinki, Helsinki University Hospital, Folkhälsans Forskningscentrum, Hospital District of Helsinki and Uusimaa, HiLIFE – Elämäntieteiden Instituutti, University of Turku, Turku University Hospital, Institute for Molecular Medicine Finland, Medical College of Wisconsin, University of Oslo, Karolinska Institutet
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,860
Funders: Helsingin Yliopisto, Helsingin ja Uudenmaan Sairaanhoitopiiri, Children’s Hospital of Wisconsin Research Institute, Finnish Cancer Institute, Suomalainen Tiedeakatemia, Magnus Ehrnroothin Säätiö, Novo Nordisk, Emil Aaltosen Säätiö, Lastentautien Tutkimussäätiö, Sigrid Juséliuksen Säätiö, Novo Nordisk Fonden, Syöpäsäätiö, Biotieteiden ja Ympäristön Tutkimuksen Toimikunta
Award: G1932718343
OpenAlex ID: W3006898491
